Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23245281 | 1.00 | USP14 (0.32) | USP14TSHRNFKB1CYP2C19SLC6A9 | |
| SCHEMBL31329480 | 0.76 | CHRM2 (0.41) | — | |
| SCHEMBL23264965 | 0.76 | CHRM2 (0.41) | — | |
| SCHEMBL30968003 | 0.74 | — | — | |
| SCHEMBL23245394 | 0.71 | FFAR3 (0.33) | TSHRNFKB1CYP2C19 | |
| SCHEMBL23245392 | 0.71 | FFAR3 (0.33) | TSHRNFKB1CYP2C19 | |
| SCHEMBL31065795 | 0.67 | CYP1A2 (0.31) | — | |
| SCHEMBL25328143 | 0.67 | — | — | |
| SCHEMBL31065791 | 0.65 | — | — | |
| SCHEMBL23245414 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11560385-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3814338-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Proteostasis Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210115057-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115057-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | USP14 246/4885TSHR 3977/4885NFKB1 455/4885 |
| US-11560385-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | USP14 246/4885TSHR 3977/4885NFKB1 455/4885 |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | USP14 246/4885TSHR 3977/4885NFKB1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.